PENUMBRA INC

Explore Penumbra’s RSU‑driven strategy, high P/E upside, and tech‑driven growth in medical devices—key insights for investors seeking value and innovation.

Penumbra insider sale: director Harpreet Grewal sold 100 shares at $328.22 on Apr 2, 2026—small, routine trading that signals portfolio rebalancing, not a strategic shift.

Insider buying at Penumbra signals confidence in its high‑growth neurovascular devices, yet its premium valuation urges cautious, value‑focused investment.

Penumbra insider sales amid Boston Scientific’s $14.5 B acquisition reveal disciplined, grant‑driven trading—insight into post‑deal value and portfolio rebalancing.

Penumbra insider selling under Rule 10b5‑1 shows disciplined portfolio management, not distress; the company’s strong neurovascular growth and robust fundamentals keep investors confident in a bullish market.